An easy conclusion from failure of completed trials is that while ABL antagonists are highly effective on CML cells addicted to the BCR-ABL oncogenic form, they elicit moderate response on cells in which the oncogenic contribution of not mutated ABL can be substituted by other signals. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.